JACKSONVILLE, Fla., Sept. 8, 2015 /PRNewswire/ -- TapImmune, Inc. (OTCQB: TPIV), a clinical-stage immunotherapy company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer & metastatic disease, will be featured as a presenting company at the SeeThruEquity Fall MicroCap Investor Conference. The presentation will take place Thursday, September 10th, 1.30-2.00 p.m. in Pershing Hub, Convene Grand Central, 101 Park Avenue, New York, NY 10178. The presentation will be given by Dr. John Bonfiglio, Strategic Advisor and Director of TapImmune.
Dr. Glynn Wilson, TapImmune’s CEO said, “We have made significant clinical progress over the past year with the completion of Phase I clinical trials in Her2/neu breast and breast and ovarian cancer. This conference is an ideal opportunity for TapImmune to provide a further update on these trials and our entry into Phase II clinical programs.”
SeeThruEquity is the premier and unbiased provider of microcap equity research and well-run, institutional and high net worth investor focused conferences. Since the inception of the firm in 2011, it has provided coverage to over 140 companies. This conference will bring together over 40 presenting companies and over 400 attendees. Participants will enjoy detailed presentations, targeted one on one meetings, and numerous networking opportunities. SeeThruEquity initiated research coverage on TapImmune in May, 2014.
About TapImmune Inc.
TapImmune Inc. is an immunotherapy company specializing in the development of innovative technologies for the treatment of cancer, including metastasis, and infectious disease. The Company’s peptide or nucleic acid-based immunotherapeutics, comprise one or multiple naturally processed epitopes (NPEs) designed to comprehensively stimulate a patients’ killer T-cells, helper T-cells and to restore or further augment antigen presentation by using proprietary nucleic acid-based expression systems. The Company’s technologies may be used as stand-alone medications or in combination with current treatment modalities. Please visit the Company’s website at www.tapimmune.com for details.
Forward-Looking Statement Disclaimer
This release contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Company’s expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are “forward-looking statements”. Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stored in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth in the Company’s most recent Form 10-K, 10-Q and other SEC filings which are available through EDGAR at www.sec.gov. The Company assumes no obligation to update the forward-looking statements.
CONTACTS:
TapImmune Inc.,
Glynn Wilson, Ph.D.
Chairman & CEO
+1(866)-359-7541
PCG Advisory
Kirin M. Smith
Chief Operating Officer
+1(646)-863-6519
Sean Leous
Chief Communications Officer
+1(646)863-8998
www.pcgadvisory.com
J. Streicher Capital, LLC
Robert Giordano
+1-917-327-3938
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/tapimmune-inc-to-present-at-the-seethruequities-fall-300138870.html
SOURCE TapImmune, Inc.
Help employers find you! Check out all the jobs and post your resume.
